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Background: Proteins can be used in drug delivery systems to improve pharmacological properties of an active
substance. Differences in pH between tissues can be utilized in order to achieve a targeted drug release at a
specific location or tissue, such as a tumor. The enamel matrix protein amelogenin has a pH dependent solubility
profile and self-assemble to form aggregates at neutral pH. This could make amelogenin useful in the design of pH
responsive drug delivery systems.
Results: In this study amelogenin was evaluated as a pH responsive component in drug delivery applications.
This was achieved by testing the ability of amelogenin to entrap/release other proteins upon changes in pH, and by
testing if amelogenin could confer pH responsiveness to an existing and versatile drug delivery system, such as
gelatin microparticles. Amelogenin was able to encapsulate bovine serum albumin and insulin, whichwere used as
model target proteins. The composite aggregates of amelogenin and target protein were formed at neutral pH and
could be reversibly solubilized at weakly acidic pH. Gelatin microparticles prepared in the presence of amelogenin,
showed a modulated structure in response to pH change, when studied by scanning electron microscopy,
compared to particles without amelogenin. At neutral pH amelogenin induced formation of pores in the particle
surface, which were not present at acidic pH, or in particles lacking amelogenin.
Conclusions: The results from this study demonstrate that amelogenin can be a useful component in drug delivery
systems in order to achieve a pH dependent response.Background
Pharmaceutical vehicles can serve several different pur-
poses during delivery of active substances, such as
extended release, increased circulation time, or protection
against degradation. Lately, drug delivery systems have also
been designed to facilitate targeting of the drug to a spe-
cific location in the body, for instance a cancer tumor. This
could be achieved by using antibodies against antigens spe-
cific for the target tissue, or alternatively by exploring dif-
ferences in chemical environment, such as differences in
pH, between different tissues orcellular locations [1,2].
Protein based drug delivery systems involve use of car-
rier proteins to improve the pharmacological properties
of the active substance. Proteins can be attractive in this
context due to their generally low toxicity and high* Correspondence: leif.bulow@tbiokem.lth.se
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distribution, and reproduction in any mediumbiocompatibility [3]. Examples of proteins in such sys-
tems include gelatin [4], albumin [5], casein [6] and fer-
ritin/apoferritin [7].
Amelogenin is an extracellular matrix protein involved
in formation of dental enamel during tooth development.
By interacting with the apatite crystals amelogenin guides
the biomineralization process that generates the highly
organized enamel [8-11]. Amelogenin has very characteris-
tic solubility properties and harbors the intrinsic ability to
self-aggregate during certain physical conditions. The ag-
gregation process is primarily affected by pH [12] and
generates nanospheres with a hydrodynamic radius of ap-
proximately 20 nm [13], but larger assemblies can also be
formed by subsequent aggregation of the nanospheres
[14,15]. The tendency to aggregate makes amelogenin
practically insoluble at physiologic pH, but the solubility
is high at weakly acidic or alkaline pH [16].ntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Amelogenin samples at pH 4 (left tube) and at pH 7
(right tube). At pH 7 amelogenin spontaneously self assembles to
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of amelogenin are valuable protein properties for drug
delivery applications. The aggregation behavior of ame-
logenin thus suggests a possible way to entrap/release
other molecules, or modulate drug delivery systems to
response to pH changes. The aim of this study was to
assess the use of amelogenin as pH responsive compo-
nent in drug delivery systems by testing its potential
in pH driven entrapment of biomolecules, as well as
to examine its ability to confer pH responsiveness to
other frequently used drug delivery systems. In this
study amelogenin encapsulation was evaluated in vitro
using two proteins of different sizes and properties,
bovine serum albumin (BSA) and insulin. In addition,
the pH dependent effects of amelogenin on gelatin micro-
particle structure were studied by scanning electron
microscopy (SEM). The biological stability of these micro-
particles was also examined by determining their resistance
against trypsin degradation.form insoluble aggregates.Results
Amelogenin production
Recombinant human amelogenin (rH174) was successfully
produced in E. coli, using a previously described method
[17]. The purified protein formed amelogenin nano-
spheres with a hydrodynamic radius of 17.9± 4.1 nm as
analyzed by dynamic light scattering analysis, suggesting
proper self-assembly properties.Molecular entrapment using amelogenin
The protein to be encapsulated (BSA or insulin) was
mixed with amelogenin during slight acidic conditions,
where amelogenin is soluble. By neutralizing the solu-
tion, by adding NaOH, amelogenin formed aggregates
(Figure 1), which were isolated and analyzed for pres-
ence of the target protein. Encapsulation experiments
with BSA showed no aggregate formation in the
absence of amelogenin, and thus all BSA was found in
the soluble fraction (supernatant) upon SDS-PAGE ana-
lysis (Figure 2A). However, when mixed with amelo-
genin in these initial encapsulation tests, a significant
portion, approximately 30% of total protein located in
the protein aggregates was BSA (the pellet). In these
tests we used an excess of BSA, and some protein
was therefore found in the soluble fraction. Entrapment
of insulin with amelogenin (Figure 2B) gave similar
results with 30% of the target protein located to the
pellet. No insulin was found to be aggregated in the
control samples.
No matter the composition, all aggregates formed at
pH ~7 in this study could be solubilized at acidic pH in
0.05% HAc, indicating a reversible aggregation process,
mainly affected by pH.Amelogenin crosslinking
Gelatin is frequently utilized for molecular encapsulation
purposes. We therefore decided to prepare mixtures of
gelatin and amelogenin and also try to stabilize these
composites by chemical crosslinking. Crosslinking of
amelogenin with glutaraldehyde (Figure 3) resulted in
rapid formation of multi- and polymeric forms, within
five minutes. The same was observed for gelatin, and
high molecular weight products were rapidly formed.
However, when amelogenin and gelatin were mixed the
subsequent addition of glutaraldehyde did not affect the
amelogenin species formed, compared to samples with-
out gelatin, indicating that very little of amelogenin was
crosslinked with the gelatin at the concentrations used in
our experimental setup.
Amelogenin promotes pH responsiveness in gelatin
microparticles
To test how pH can influence a drug delivery system
composed partly of amelogenin, gelatin microparticles
were created with and without amelogenin. The particles
were incubated at pH 7 and pH 4 and analyzed with
SEM to characterize the effect of amelogenin on the
microparticle structure (Figure 4). Particle size and size
distribution were not significantly affected by presence of
amelogenin and in general the particles were spherical
with a diameter of approximately 40–60 μm. At 1,500 x
magnification the surface of the particles partly appeared
heterogeneous, with both smooth and rough areas on
the same particle. These different surface types could be
observed on both kind of particles, but in general amelo-
genin containing particles exhibited a higher degree of
Figure 2 SDS-PAGE analysis of encapsulation experiments with
amelogenin (AMG) mixed with BSA (Panel A) or insulin (Ins.)
(Panel B). By changing the pH from weakly acidic to neutral the
aggregation of amelogenin is induced, which entraps the target
molecule. Proteins captured in the aggregates are released upon
acidification will end up in the solubilized pellet sample (P).
The soluble fraction (S) contains proteins not precipitated or
captured by the neutralization. The three subpanels are taken from
the same gel. Blue arrowsindicate amelogenin, green arrow indicates
BSA, and red arrow indicates insulin.
Figure 3 SDS-PAGE analysis of amelogenin (AMG) and gelatin
samples crosslinked with glutaraldehyde. The samples have been
crosslinked for 0, 5, 30 minutes, and 2 h. Crosslinking of amelogenin
in the presence of gelatin does not alter the size of the amelogenin
multimers, compared to crosslinking in the absence of gelatin.
This indicates that only a minor portion of the amelogenin molecules
are covalently linked with gelatin during the glutaraldehyde
crosslinking reaction.
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ence between the amelogenin containing particles and
the control particles was observed at high magnification
(50,000 x). The structure of the control gelatin particles
looked smooth, even in areas that had a rough appear-
ance at lower magnification, but in the amelogenin
containing particles small pores could be observed on
the particle surface. The surface pores were present
in areas that looked both smooth and rough in lowermagnification. The porous surfaces were only observed
in the pH 7 samples when amelogenin is insoluble. The
particles incubated at pH 4 showed no such pores, but
the amelogenin particles had a cracked surface, in the
highest magnification that was not observed in the con-
trol particles.
Amelogenin increases microparticle stability against
trypsin degradation
Microparticles supplemented with aniline blue were
subjected to incubation with trypsin to determine the
particle stability against proteolytic degradation, as a
method of mimicking small intestine digestion. The
accumulation of aniline blue in the sample supernatants
was concomitant with degradation of the microparticles,
and no aniline blue was released from the particles in
the absence of trypsin. Both the amelogenin containing
particles and the control particles were degraded by tryp-
sin, but the amelogenin containing particles were signifi-
cantly more resistant to the proteolysis (Figure 5). The
biggest difference was observed after 1 h incubation with
trypsin, where the major fraction (85%) of control parti-
cles were degraded, while 50% of the amelogenin parti-
cles were still intact. After 2 h both kinds of particles
were completely degraded and no further increase in ab-
sorbance was detected.
Discussion
The use of a drug delivery platform composed of natur-
ally self-assembled polypeptides is often attractive due to
Figure 4 SEM analysis of microparticles made from gelatin, with (B, D, F, H, J, L) and without (A, C, E, G, I, K) amelogenin (AMG).
The particles were incubated at pH 7 (A-F) or at pH 4 (G-L) before preparation for SEM. The presence of amelogenin affected the surface structure
of the particles at pH 7 and small pores were observed in the amelogenin containing particles (panel F), but not in the control particles without
amelogenin (panel E). A difference in the structure between amelogenin and control particles was also observed at pH 4 (panel G-L), but no
pores seemed to form at acidic pH.
Bonde and Bülow BMC Biotechnology 2012, 12:25 Page 4 of 7
http://www.biomedcentral.com/1472-6750/12/25its inherent biocompatibility and biodegradability. Ame-
logenin is a non-toxic and affordable protein that can
easily be produced in large-scales. It has been used clin-
ically for wound healing and dental applications forFigure 5 Analysis of gelatin and gelatin/amelogenin (AMG)
microparticle degradation at pH 7.0 in presence of trypsin.
The bars indicate the accumulated release of aniline blue from the
particles upon proteolytic degradation, as measured by aborbance at
600 nm. The error bars represent the standard deviation based on
four replicates. The amelogenin containing microparticles showed an
improved resistance to trypsin degradation after 1 h incubation.several years with no side effects reported [18-20]. Even
if amelogenin often is viewed largely as an enamel asso-
ciated protein, it has recently been found to be expressed
in several tissues including brain, eye, cartilage and bone
[21].
In order to target the release of a drug to a specific lo-
cation in the body, differences in pH between tissues or
cellular compartments can be utilized. For example,
increased drug release at acidic pH can target a drug to a
cancer tumor where the pH often is more acidic.
In order to be functional the drug delivery system must
be responsive to the pH change at the target site. The
enamel matrix protein amelogenin has a solubility profile
that is greatly affected by pH (Figure 1), which can be
potentially useful in creating a pH response in drug de-
livery systems composed at least partly of amelogenin. In
this study the use of amelogenin as a pH responsive
component was assessed by testing its ability to entrap/
release other proteins upon changes in pH, and by study-
ing the effect of pH change on the structure of gelatin
microparticles containing amelogenin.
The results in this study demonstrate that amelogenin
can be used to entrap other proteins, in a reversible
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gether with amelogenin (Figure 2), suggesting formation
of composite particles, containing both amelogenin and
the target proteins. No BSA or insulin were found in the
pellet of the control samples, indicating that the aggre-
gates, formed together with amelogenin, were indeed
composite aggregates, and not simply a mixture of two
different types of aggregates. Interestingly, the presence
of BSA also seemed to increase the amount of amelo-
genin in the soluble fraction, compared to the amelo-
genin control. Both amelogenin and BSA have a
hydrophobic character and they may interact with each
other both in solution and during aggregation, leading
to increased solubility of the amelogenin part. All the
amelogenin composite aggregates could be completely
solubilized at acidic conditions. The reversibility of the
aggregation process makes it possible to release the pro-
tein entrapped with amelogenin, following a decrease in
pH. Most proteins were susceptible for entrapment in an
amelogenin matrix and the amelogenin particles could
carry substantial amounts of an entrapped target protein,
up to 30%. Out of the proteins tested, only lysozyme en-
capsulation was not achieved in this study, probably due
to strong protein-protein intermolecular interactions
affecting amelogenin aggregation. As opposed to BSA (pI
4.8) and insulin (pI 5.3) lysozyme has an isolectric point
(pI 10.7) in the far alkaline range. Although hydrophobic
interactions are essential for the initial amelogenin nano-
sphere formation, the charged and hydrophilic C-
terminus has a pronounced effect on the amelogenin ag-
gregation. At neutral pH, lysozyme is positively charged
and can thereby perturb and interfere with the native
intermolecular amelogenin interactions. The results from
this study therefore point to a potential use of amelogenin
in targeted release of pharmaceutical proteins, induced by
acidification, but the charge of the entrapped protein may
be critical for proper particle formation.
To test if the pH dependent aggregation properties of
amelogenin could be used further to confer pH sensi-
tivity also to other drug delivery systems, without any
inherent pH responsiveness, gelatin/amelogenin micro-
particles were prepared using an emulsion-based method.
The purpose of mixing amelogenin with gelatin was to de-
termine if only a minor fraction of amelogenin could pro-
vide a response to pH changes in the gelatin particles,
potentially giving the composite particles beneficial prop-
erties from both components. The gelatin microparticles
containing amelogenin displayed a modulated structure
compared to control particles without amelogenin. The
difference was most pronounced at pH 7 where the
amelogenin containing particles had a porous surface
not observed in the control particles (Figure 4). At pH 4,
a difference in the surface structure was also observed
between the amelogenin and control particles, indicatingthat the presence of amelogenin may have effect on the
particles at both acidic and neutral pH. However, the por-
ous structure was confined to the pH 7 particles, suggest-
ing a more pronounced effect of amelogenin on the
particle surface structure at neutral pH. At pH 4, the gel-
atin particles appeared to lose some of their structural
integrity and adapt a more flat morphology. This effect
was less pronounced in the amelogenin containing parti-
cles, suggesting a stabilizing effect of amelogenin. The
results clearly indicate that the amelogenin containing gel-
atin particles change from having a porous surface at pH
7, to having a non-porous surface when pH becomes
acidic, or vice versa. The analysis carried out in this study
cannot distinguish if the pores extend deeper into the par-
ticles, or if they are isolated to the surface layer. However,
we propose that the change in microparticle surface por-
osity at pH 7 is an effect of the amelogenin solubility pro-
file and the tendency of amelogenin to self-assemble at
neutral pH. A change in amelogenin protein structure,
due to changes in pH, could modulate the interaction
between both amelogenin molecules and components in
the gelatin, leading to a modified structure of the micro-
particles. Crosslinking of amelogenin with glutaraldehyde
under the conditions used does not covalently attach ame-
logenin to gelatin (Figure 3), making it possible for amelo-
genin to act independently of the gelatin molecules inside
the particles. The observed changes in porosity are likely
to have a large effect on particle release, degradation, tis-
sue penetration, and other pharmacologically
important properties. If a porous or non-porous surface is
most beneficial at a given condition depends on the appli-
cation, but having the ability to change between these two
states can be helpful to achieve a pH mediated delivery of
substances from the particle. In addition, the results
obtained in this study are supported by previous observa-
tions that an amelogenin gel, formed at pH 6.8, develops
voids in response to temperature, turning the gel opaque
when the temperature is changed from 4°C to 24°C [22].
The temperatures used in our study correspond with
those where the voids are formed. In our study, amelo-
genin comprises only a small fraction (~2.5%) of the solid
material in the microparticles, indicating that amelogenin
confers a potent response to pH changes, even after cross-
linking of the particle with glutaraldehyde. This could
be a useful property when designing new drug delivery sys-
tems, or in other processes where pH responsiveness
is desirable.
The amelogenin containing microparticles proved to
be more resistant to trypsin degradation compared to
the control particles without amelogenin (Figure 5).
Since amelogenin is insoluble at pH 7, at which the pro-
teolysis was performed, it may be a poor trypsin sub-
strate and therefore shield the particle from degradation.
Decreased trypsin sensitivity can be an advantage if an
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release further down the gastrointestinal tract. The data
from this study suggest that drug delivery systems com-
posed partly of amelogenin could have an increased
tolerance towards trypsin degradation.
In our current study, we utilized native amelogenin
which is insoluble between pH 6 and 7.5. By modifying
the surface properties of amelogenin by for instance site-
directed mutagenesis, this pH range may be modified to
cover a desired pH optimum or shifting it to a wider or
more narrow range. Particularly, the charged residues in
the C-terminal end of amelogenin have proved to be crit-
ical in the amelogenin self-assembly [9,23]. By dissecting
the influence of these residues by protein engineering
methods novel amelogenins can be obtained.Conclusions
The results from this study clearly show that the pH
dependent solubility of amelogenin makes it useful as a
component in drug delivery systems, in order to create a
response to changes in pH. An effect on both the entrap-
ment/release of a target protein, and on microparticle
surface porosity could be observed. Additionally, amelo-
genin also decreased trypsin degradation of microparti-
cles. Human amelogenin can be made readily available
by recombinant means and is suitable for use in pharma-
ceutical formulations since no clinical side effects have
been reported over the years despite extensive use in
particuarly dental surgery.Methods
Preparation of recombinant amelogenin
Recombinant amelogenin (rH174) was expressed and
purified from Escherichia coli BL21 (DE3) cells harbor-
ing a pET11 vector (Novagen) with an insert encod-
ing human amelogenin (Swissprot Q99217, isoform 1,
excluding the signal peptide) cloned between the NdeI
and BamHI sites. The cells were cultivated at 37°C in
TB-medium (100 ml in 500 ml shake flasks) and induced
4 h post inoculum with 5 mM lactose. The cells were
harvested with centrifugation at 5,000 g for 10 minutes.
Amelogenin was purified according to an acid/heat treat-
ment method [17]. Briefly, the cell pellet was
suspended in 3% HAc and heat treated at 80°C for
20 minutes. The insoluble fraction was removed by cen-
trifugation at 20,000 g for 20 minutes, and the super-
natant, containing soluble amelogenin, was collected.
The amelogenin solution was dialyzed against 0.05%
HAc, aliquoted and lyophilized. The purified amelogenin
was analyzed by SDS-PAGE and the ability to form
nanospheres was verified by dynamic light scattering
(Zetasizer Nano, Malvern Instruments) in 100 mM
HEPES, pH 8.0, at a protein concentration of 2 mg/ml.Molecular encapsulation with amelogenin
Use of amelogenin for pH dependent entrapment of
other proteins was characterized using BSA and insulin
as target molecules. For encapsulation experiments solu-
tions of amelogenin was prepared by dissolving lyophi-
lized amelogenin in 0.05% HAc. Concentrations of the
amelogenin stock solutions used were between 10–
50 mg/ml. The proteins to be encapsulated were dis-
solved in 0.05% HAc or in H2O and mixed with the ame-
logenin stock solution, keeping the pH below the point
of amelogenin aggregation. To induce the encapsulation/
aggregation the pH was adjusted to ~7.0, by slowly add-
ing NaOH. The formed aggregates were separated from
the soluble fraction by centrifugation, and the pellet was
washed with 100 mM sodium phosphate buffer, pH 7.0.
The pellet was re-solubilized by addition of 0.05% HAc.
Samples from the different encapsulation steps were col-
lected and analyzed with SDS-PAGE.
Crosslinking of amelogenin and gelatin
In order to test the effects of glutaraldehyde crosslinking
on amelogenin, gelatin, and mixtures thereof, the pro-
teins were dissolved in 100 mM sodium phosphate buf-
fer, pH 8.0, at 37°C. Glutaraldehyde was added to the
samples to a final concentration of 0.5%, followed by in-
cubation at 37°C for various periods of time (0 minutes
to 2 hours). For each sample the crosslinking reaction
was quenched with Tris by adding one volume of SDS-
PAGE loading buffer (2% SDS, 50 mM Tris–HCl, pH
6.8, 10% glycerol, 1% mercaptoethanol, 12.5 mM EDTA,
0.02% bromophenol blue). All samples were subse-
quently analyzed by SDS-PAGE.
Gelatin/amelogenin crosslinked microparticles
Composite micoparticles containing gelatin and amelo-
genin were prepared, in order to test the effects of ame-
logenin on their property and structure. Microparticles
without amelogenin were also made and used as a con-
trol. The protocol used for micoparticle formation is
similar to what has been previously described [4], but with
some modifications. A mixture of gelatin (100 mg/ml) and
recombinant amelogenin (2.5 mg/ml) solubilized in H2O
at 40°C was transferred to sunflower oil to create an emul-
sion. Glutaraldehyde was added to the gelatin/amelogenin
mixture to a concentration of 0.5% just before transfer to
the sunflower oil. The emulsion was continuously stirred
at 1 000 rpm and was incubated at 40°C for 30 minutes,
followed by incubation on ice for 10 minutes. The micro-
particles were then isolated by adding acetone to the emul-
sion, which made the particles concentrate in the
interphase. The oil and acetone phases were removed and
the particles were transferred to a sintered glass filter and
washed extensively with acetone. The particles were dried
in a flow hood andsubsequently in a vaccum exsiccator.
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as above, but the gelatin solution was supplemented with
4 mg/ml aniline blue.
Physical structure of the composite microparticles
To analyze the effect of pH on the gelatin/amelogenin
composite particles they were incubated for 1.5 h in ei-
ther 20 mM HAc pH 4.0 or in 20 mM sodium phosphate
pH 7.0. The particles were then transferred to scanning elec-
tron micropcopy (SEM) sample stubs and dried in an exsic-
cator, followed by drying using a lyophilizer vaccum pump.
The samples were then sputter coated with gold/palladium
and analyzed on an SEM instrument (Jeol JSM 6700 F NT)
with 5 kV acceleration voltage.
Proteolytic degradation of the microparticles
To determine the stability of the gelatin/amelogenin par-
ticles against proeolytic degradation the particles were
incubated in 20 mM sodium phosphate pH 7.0, contain-
ing 5 μg/ml bovine pancreatic trypsin. The particles used
in this experiment were supplemented with aniline blue
for simple spectroscopic detection of particle degrad-
ation. The particle concentration used was 10 mg/ml
and both amelogenin/gelatin particles and control parti-
cles without amelogenin were tested (four replicates/
sample). The degradation was analyzed by measuring the
absorbance of the supernatant at 600 nm over time on a
Beckman Coulter DU 800 spectrophotometer (1 cm path
length).
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